Analyst Ratings for Atrium Therapeutics (RNA)
RNA Rating Summary
RNA Price Target Summary
- Highest: $74.00 (TD Cowen)
- Lowest: $25.00 (Leerink)
- Average: $54.45
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$54.45 (+272.2%)
* Over Last 12-Mos
Rating Score: 5.2 / 10
Percentile Rank: 56%
Avg. $ Target:
$54.45 (+272.2%)
* Over Last 12-Mos
Rating Score: 5.2 / 10
Percentile Rank: 56%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/6/2026 | H.C. Wainwright | N/A | New Coverage | Buy (N/A) |
25.00 (N/A) |
11.74 (14.63) |
24.62% | Details |
| 6/18/2026 | Cantor Fitzgerald | Kristen Kluska | New Coverage | Neutral (N/A) |
25.00 (N/A) |
12.48 (14.63) |
17.23% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
